Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4799011
Max Phase: Preclinical
Molecular Formula: C30H34ClNO2
Molecular Weight: 439.60
Molecule Type: Unknown
Associated Items:
ID: ALA4799011
Max Phase: Preclinical
Molecular Formula: C30H34ClNO2
Molecular Weight: 439.60
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cl.OCCC/C(=C(\c1ccc(O)cc1)c1ccc(C2CCN(C3CC3)C2)cc1)c1ccccc1
Standard InChI: InChI=1S/C30H33NO2.ClH/c32-20-4-7-29(23-5-2-1-3-6-23)30(25-12-16-28(33)17-13-25)24-10-8-22(9-11-24)26-18-19-31(21-26)27-14-15-27;/h1-3,5-6,8-13,16-17,26-27,32-33H,4,7,14-15,18-21H2;1H/b30-29+;
Standard InChI Key: QDNJZFSSWGBXNV-BXGDTPBJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 439.60 | Molecular Weight (Monoisotopic): 439.2511 | AlogP: 6.08 | #Rotatable Bonds: 8 |
Polar Surface Area: 43.70 | Molecular Species: BASE | HBA: 3 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 9.07 | CX Basic pKa: 9.67 | CX LogP: 5.10 | CX LogD: 3.82 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.42 | Np Likeness Score: 0.00 |
1. Kim J,Hwang H,Yoon H,Lee JE,Oh JM,An H,Ji HD,Lee S,Cha E,Ma MJ,Kim DS,Lee SJ,Kadayat TM,Song J,Lee SW,Jeon JH,Park KG,Lee IK,Jeon YH,Chin J,Cho SJ. (2020) An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer., 205 [PMID:32758860] [10.1016/j.ejmech.2020.112501] |
Source(1):